[{"id":"2c213921-d571-4dca-a937-18656828733b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05657743","created_at":"2024-01-03T16:18:20.569Z","updated_at":"2025-02-25T16:33:14.056Z","phase":"","brief_title":"A Feasibility and Safety Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Advanced Pancreatic Cancer","source_id_and_acronym":"NCT05657743","lead_sponsor":"Alpha Tau Medical LTD.","biomarkers":" CD8 • CD4 • CD69 • TNFRSF9","pipe":"","alterations":" ","tags":["CD8 • CD4 • CD69 • TNFRSF9"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 08/16/2023","start_date":" 08/16/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2025-02-07"},{"id":"56bb338a-9a55-47ed-87d8-9a54d97136da","acronym":"","url":"https://clinicaltrials.gov/study/NCT03595124","created_at":"2021-01-18T17:40:40.562Z","updated_at":"2025-02-25T16:31:25.872Z","phase":"Phase 2","brief_title":"A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)","source_id_and_acronym":"NCT03595124","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • PD-1 • CD38 • PTPRC • CD69 • TFE3 • CD14 • CD24 • ITGAM • FOXP3","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8 • PD-1 • CD38 • PTPRC • CD69 • TFE3 • CD14 • CD24 • ITGAM • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • axitinib • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/08/2019","start_date":" 01/08/2019","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 01/23/2026","study_completion_date":" 01/23/2026","last_update_posted":"2025-02-07"},{"id":"53f4eddd-132e-4531-8be4-d3f2264f7d40","acronym":"","url":"https://clinicaltrials.gov/study/NCT06790797","created_at":"2025-02-25T18:39:59.893Z","updated_at":"2025-02-25T18:39:59.893Z","phase":"","brief_title":"Investigating the Biomarkers in Tumor and Peripheral Blood to Evaluate the Efficacy of Cancer Immunotherapy in Chest Cancer Patients","source_id_and_acronym":"NCT06790797","lead_sponsor":"Zhao Jun","biomarkers":" CD8 • IFNG • IL2RA • CD4 • CD69 • TNFRSF9 • FOXP3 • ENTPD1","pipe":"","alterations":" ","tags":["CD8 • IFNG • IL2RA • CD4 • CD69 • TNFRSF9 • FOXP3 • ENTPD1"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 02/12/2023","start_date":" 02/12/2023","primary_txt":" Primary completion: 07/30/2027","primary_completion_date":" 07/30/2027","study_txt":" Completion: 07/30/2027","study_completion_date":" 07/30/2027","last_update_posted":"2025-01-24"},{"id":"f86dd180-9964-44e8-9f7d-13e77891a73a","acronym":"STOPTRAFFIC-1","url":"https://clinicaltrials.gov/study/NCT04599140","created_at":"2021-02-21T15:52:40.898Z","updated_at":"2025-02-25T14:29:40.279Z","phase":"Phase 1/2","brief_title":"SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial","source_id_and_acronym":"NCT04599140 - STOPTRAFFIC-1","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRAF • CD8 • CD4 • CD69 • IRF2","pipe":"","alterations":" ","tags":["BRAF • CD8 • CD4 • CD69 • IRF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • SX-682"],"overall_status":"Recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 10/14/2020","start_date":" 10/14/2020","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2025-01-17"},{"id":"10e7c484-a234-4aa3-b3ff-69b3ed1da252","acronym":"CA209-324","url":"https://clinicaltrials.gov/study/NCT02648997","created_at":"2024-01-24T15:18:16.455Z","updated_at":"2025-02-25T14:36:04.275Z","phase":"Phase 2","brief_title":"An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma","source_id_and_acronym":"NCT02648997 - CA209-324","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" PD-L1 • PD-1 • IL2RA • CD4 • CD69 • FOXP3","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • PD-1 • IL2RA • CD4 • CD69 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-12-19"},{"id":"7de0a964-4fdf-4f6a-8b41-30ece66dedf5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05047094","created_at":"2024-01-03T19:18:38.155Z","updated_at":"2024-07-02T16:35:02.678Z","phase":"","brief_title":"A Safety and Efficacy Study for Combinational Treatment of DaRT and Check Point Inhibitor for Recurrent Unresectable or mHNSCC","source_id_and_acronym":"NCT05047094","lead_sponsor":"Alpha Tau Medical LTD.","biomarkers":" CD8 • CD4 • CD69 • TNFRSF9","pipe":"","alterations":" ","tags":["CD8 • CD4 • CD69 • TNFRSF9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 11/02/2021","start_date":" 11/02/2021","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-05-17"},{"id":"c47979e1-5e6a-49c1-ade7-1d82b5e9e5d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06026943","created_at":"2024-05-20T20:33:53.680Z","updated_at":"2024-07-02T16:35:03.105Z","phase":"","brief_title":"Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer Emitters for the Treatment of Locally Advanced Pancreatic Cancer","source_id_and_acronym":"NCT06026943","lead_sponsor":"Alpha Tau Medical LTD.","biomarkers":" CD8 • CD4 • CD69 • TNFRSF9","pipe":"","alterations":" ","tags":["CD8 • CD4 • CD69 • TNFRSF9"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 09/01/2024","start_date":" 09/01/2024","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2024-05-17"},{"id":"0f0997b4-e016-4774-9c8c-8817ae0fe8c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05462496","created_at":"2022-07-18T14:01:45.193Z","updated_at":"2024-07-02T16:35:28.767Z","phase":"Phase 2","brief_title":"Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer","source_id_and_acronym":"NCT05462496","lead_sponsor":"Icahn School of Medicine at Mount Sinai","biomarkers":" CD38 • IL2RA • CD69 • ISG20","pipe":"","alterations":" ","tags":["CD38 • IL2RA • CD69 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 3","initiation":"Initiation: 03/13/2023","start_date":" 03/13/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-11-18"},{"id":"4f13e8f8-3758-4b59-88b8-7db2cdc3ba0f","acronym":"HPVDCVax","url":"https://clinicaltrials.gov/study/NCT06007092","created_at":"2023-08-23T15:10:57.492Z","updated_at":"2024-07-02T16:35:39.222Z","phase":"Phase 1/2","brief_title":"Therapeutic Vaccine in Patients With Human Papillomavirus HPV-positive Oropharyngeal Cancer","source_id_and_acronym":"NCT06007092 - HPVDCVax","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" CD69 • TNFRSF9","pipe":"","alterations":" ","tags":["CD69 • TNFRSF9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD40HVac"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 07/31/2023","start_date":" 07/31/2023","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2023-08-23"},{"id":"9ae4eede-f757-4258-926b-cb6caf976257","acronym":"","url":"https://clinicaltrials.gov/study/NCT05967533","created_at":"2023-08-01T16:10:23.357Z","updated_at":"2024-07-02T16:35:41.462Z","phase":"Phase 1","brief_title":"The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors","source_id_and_acronym":"NCT05967533","lead_sponsor":"University of California, Davis","biomarkers":" CD8 • IFNG • IL6 • IL2RA • CD4 • CD69 • IL2 • IL10 • LAMP1 • TGFB1 • FOXP3 • IL17A • ISG20","pipe":" | ","alterations":" IFNG expression","tags":["CD8 • IFNG • IL6 • IL2RA • CD4 • CD69 • IL2 • IL10 • LAMP1 • TGFB1 • FOXP3 • IL17A • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IFNG expression"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 06/02/2023","start_date":" 06/02/2023","primary_txt":" Primary completion: 06/02/2025","primary_completion_date":" 06/02/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-08-01"},{"id":"2d513838-1520-48c5-95c6-510610c1ab07","acronym":"","url":"https://clinicaltrials.gov/study/NCT05789498","created_at":"2023-03-29T14:03:25.617Z","updated_at":"2024-07-02T16:35:52.066Z","phase":"","brief_title":"Investigating the Biomarkers in Tumor and Peripheral Blood to Evaluate the Efficacy of Cancer Immunotherapy in Chest Cancer Patients","source_id_and_acronym":"NCT05789498","lead_sponsor":"Zhao Jun","biomarkers":" PD-L1 • CD8 • IFNG • IL2RA • CD4 • CD69 • TNFRSF9 • FOXP3 • ENTPD1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • CD8 • IFNG • IL2RA • CD4 • CD69 • TNFRSF9 • FOXP3 • ENTPD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 02/12/2023","start_date":" 02/12/2023","primary_txt":" Primary completion: 03/30/2024","primary_completion_date":" 03/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2023-03-29"},{"id":"d3399d53-3142-4fb8-8731-3da5f0cf0026","acronym":"TITAN-RCC","url":"https://clinicaltrials.gov/study/NCT02917772","created_at":"2021-08-04T19:53:08.805Z","updated_at":"2025-02-25T14:36:42.250Z","phase":"Phase 2","brief_title":"Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma","source_id_and_acronym":"NCT02917772 - TITAN-RCC","lead_sponsor":"AIO-Studien-gGmbH","biomarkers":" CD8 • PD-1 • PD-L2 • IL2RA • CD69 • ICOS • IL10 • CD14 • CD27 • LAMP1 • ITGAM • FAS • FOXP3 • IL17A • IL3RA • ITGAX • B3GAT1 • CD1C • CLEC4C","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8 • PD-1 • PD-L2 • IL2RA • CD69 • ICOS • IL10 • CD14 • CD27 • LAMP1 • ITGAM • FAS • FOXP3 • IL17A • IL3RA • ITGAX • B3GAT1 • CD1C • CLEC4C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Completed","enrollment":" Enrollment 200","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 10/01/2021","primary_completion_date":" 10/01/2021","study_txt":" Completion: 10/01/2022","study_completion_date":" 10/01/2022","last_update_posted":"2022-10-06"},{"id":"d0527478-cd05-4416-b5a5-992a14d14ac7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03385486","created_at":"2021-05-11T12:52:51.133Z","updated_at":"2024-07-02T16:36:11.051Z","phase":"Phase 1","brief_title":"Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors","source_id_and_acronym":"NCT03385486","lead_sponsor":"Taiga Biotechnologies, Inc.","biomarkers":" CD69","pipe":"","alterations":" ","tags":["CD69"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TBX-3400"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 06/02/2019","start_date":" 06/02/2019","primary_txt":" Primary completion: 02/01/2023","primary_completion_date":" 02/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-05-03"},{"id":"f0fc99b5-d1de-433b-93c4-9263a9eb22b3","acronym":"BIOREN","url":"https://clinicaltrials.gov/study/NCT03628859","created_at":"2021-01-18T17:49:29.058Z","updated_at":"2024-07-02T16:36:15.363Z","phase":"","brief_title":"BIOREN (Predictive BIOmarkers in Metastatic RENal Cancer)","source_id_and_acronym":"NCT03628859 - BIOREN","lead_sponsor":"Centre Leon Berard","biomarkers":" IFNG • IL2RA • CD69 • NCAM1 • IL10 • ENTPD1 • B3GAT1 • ISG20 • KLRC1","pipe":"","alterations":" ","tags":["IFNG • IL2RA • CD69 • NCAM1 • IL10 • ENTPD1 • B3GAT1 • ISG20 • KLRC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • sunitinib"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/21/2018","start_date":" 12/21/2018","primary_txt":" Primary completion: 06/01/2023","primary_completion_date":" 06/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-03-15"},{"id":"91376b42-a448-49fc-b024-9ff401ca6c3b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04640246","created_at":"2021-05-11T12:53:09.487Z","updated_at":"2024-07-02T16:36:17.708Z","phase":"Phase 1/2","brief_title":"Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies","source_id_and_acronym":"NCT04640246","lead_sponsor":"Taiga Biotechnologies, Inc.","biomarkers":" CD69","pipe":"","alterations":" ","tags":["CD69"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TBX-3400"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/25/2021","start_date":" 01/25/2021","primary_txt":" Primary completion: 01/01/2023","primary_completion_date":" 01/01/2023","study_txt":" Completion: 04/01/2023","study_completion_date":" 04/01/2023","last_update_posted":"2022-02-02"},{"id":"b5ce9f6f-90bd-4e6c-8af0-4771e28aea48","acronym":"","url":"https://clinicaltrials.gov/study/NCT03021993","created_at":"2021-01-18T14:52:12.866Z","updated_at":"2025-02-25T14:37:08.309Z","phase":"Phase 2","brief_title":"Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer","source_id_and_acronym":"NCT03021993","lead_sponsor":"Medical University of South Carolina","biomarkers":" CD8 • IFNG • CD4 • CD69 • ICOS • IL10 • GZMB • TGFB1 • FOXP3","pipe":" | ","alterations":" CD8 expression • IFNG expression • IL2 expression","tags":["CD8 • IFNG • CD4 • CD69 • ICOS • IL10 • GZMB • TGFB1 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression • IFNG expression • IL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 05/30/2017","start_date":" 05/30/2017","primary_txt":" Primary completion: 11/15/2021","primary_completion_date":" 11/15/2021","study_txt":" Completion: 11/15/2021","study_completion_date":" 11/15/2021","last_update_posted":"2021-12-13"},{"id":"b1fc3749-e95d-4a68-ab16-6259c58fc366","acronym":"","url":"https://clinicaltrials.gov/study/NCT05011097","created_at":"2021-08-18T14:53:35.366Z","updated_at":"2024-07-02T16:36:26.202Z","phase":"Phase 1","brief_title":"A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT05011097","lead_sponsor":"Wuhan YZY Biopharma Co., Ltd.","biomarkers":" IFNG • IL6 • TNFA • PTPRC • CD69 • IL2 • NCAM1 • IL10 • CD14 • IFNA1","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • PTPRC • CD69 • IL2 • NCAM1 • IL10 • CD14 • IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Y150"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 07/08/2021","start_date":" 07/08/2021","primary_txt":" Primary completion: 07/30/2023","primary_completion_date":" 07/30/2023","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2021-08-18"},{"id":"5fad71d4-a395-4a9d-9bc6-39b3d673e45a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01276236","created_at":"2021-01-29T07:01:30.935Z","updated_at":"2024-07-02T16:36:33.752Z","phase":"Phase 2","brief_title":"Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)","source_id_and_acronym":"NCT01276236","lead_sponsor":"University of California, San Francisco","biomarkers":" CD8 • CD38 • CD4 • CD69","pipe":" | ","alterations":" CD38 positive • CD8 negative","tags":["CD8 • CD38 • CD4 • CD69"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 positive • CD8 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Selzentry (maraviroc)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 03/09/2011","start_date":" 03/09/2011","primary_txt":" Primary completion: 01/31/2015","primary_completion_date":" 01/31/2015","study_txt":" Completion: 04/30/2015","study_completion_date":" 04/30/2015","last_update_posted":"2021-03-05"},{"id":"9191d14a-5359-4697-90d1-ac86b9cf4e22","acronym":"","url":"https://clinicaltrials.gov/study/NCT02163057","created_at":"2021-01-18T10:04:15.979Z","updated_at":"2024-07-02T16:36:35.792Z","phase":"Phase 1/2","brief_title":"Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT02163057","lead_sponsor":"Inovio Pharmaceuticals","biomarkers":" CD8 • CD69 • TNFRSF9 • GZMB • FOXP3 • GZMA • PRF1","pipe":" | ","alterations":" TILs","tags":["CD8 • CD69 • TNFRSF9 • GZMB • FOXP3 • GZMA • PRF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e INO-3112"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 08/13/2014","start_date":" 08/13/2014","primary_txt":" Primary completion: 01/23/2017","primary_completion_date":" 01/23/2017","study_txt":" Completion: 01/23/2017","study_completion_date":" 01/23/2017","last_update_posted":"2021-01-22"},{"id":"76bb18a2-5df2-4863-a55d-60f617f380ed","acronym":"NKCD160MEL","url":"https://clinicaltrials.gov/study/NCT04477876","created_at":"2021-05-11T12:53:06.909Z","updated_at":"2024-07-02T16:36:43.013Z","phase":"","brief_title":"Study of CD160, an Activating NK Cell Receptor, in Melanoma: a Potential Therapeutic Target?","source_id_and_acronym":"NCT04477876 - NKCD160MEL","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" CD69","pipe":"","alterations":" ","tags":["CD69"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 09/01/2020","start_date":" 09/01/2020","primary_txt":" Primary completion: 12/15/2027","primary_completion_date":" 12/15/2027","study_txt":" Completion: 12/15/2027","study_completion_date":" 12/15/2027","last_update_posted":"2020-07-20"},{"id":"e90d90e5-33e6-4be3-bd2c-8d8dccd30023","acronym":"","url":"https://clinicaltrials.gov/study/NCT04355806","created_at":"2021-01-18T21:03:23.571Z","updated_at":"2024-07-02T16:36:45.824Z","phase":"","brief_title":"Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors","source_id_and_acronym":"NCT04355806","lead_sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","biomarkers":" CD8 • IFNG • IL6 • TNFA • CXCL8 • CXCL10 • CD4 • CD69 • IL2 • IL10 • CCL2 • CSF2 • IL13 • IL1B • IL4 • IL5","pipe":" | ","alterations":" CD8 expression","tags":["CD8 • IFNG • IL6 • TNFA • CXCL8 • CXCL10 • CD4 • CD69 • IL2 • IL10 • CCL2 • CSF2 • IL13 • IL1B • IL4 • IL5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 05/31/2023","study_completion_date":" 05/31/2023","last_update_posted":"2020-04-21"},{"id":"62e2d243-ba6a-43d7-ac99-c3ee140f013e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00894413","created_at":"2021-01-29T06:59:30.386Z","updated_at":"2024-07-02T16:36:58.952Z","phase":"Phase 2","brief_title":"A Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract","source_id_and_acronym":"NCT00894413","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD8 • CD4 • CD69","pipe":"","alterations":" ","tags":["CD8 • CD4 • CD69"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 05/08/2007","start_date":" 05/08/2007","primary_txt":" Primary completion: 03/01/2012","primary_completion_date":" 03/01/2012","study_txt":" Completion: 03/01/2012","study_completion_date":" 03/01/2012","last_update_posted":"2019-06-11"},{"id":"3352753e-aefb-46b9-a859-11eaadd3d587","acronym":"","url":"https://clinicaltrials.gov/study/NCT01460875","created_at":"2021-01-18T06:04:28.765Z","updated_at":"2025-02-25T16:01:59.871Z","phase":"","brief_title":"Recombinant Interferon Alfa-2b in Treating Patients With Melanoma","source_id_and_acronym":"NCT01460875","lead_sponsor":"William Carson","biomarkers":" CD69 • IFNA1","pipe":"","alterations":" ","tags":["CD69 • IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Intron A (interferon α-2b)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 04/22/2008","start_date":" 04/22/2008","primary_txt":" Primary completion: 01/05/2014","primary_completion_date":" 01/05/2014","study_txt":" Completion: 01/05/2014","study_completion_date":" 01/05/2014","last_update_posted":"2018-11-02"},{"id":"850be3ec-257d-4c60-a688-027df10aa9ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT01347996","created_at":"2021-01-18T05:30:16.403Z","updated_at":"2024-07-02T16:37:16.006Z","phase":"Phase 4","brief_title":"Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia","source_id_and_acronym":"NCT01347996","lead_sponsor":"Cytovia, Inc.","biomarkers":" CD8 • IFNG • IL2RA • CD4 • CD69 • NCAM1 • ISG20","pipe":"","alterations":" ","tags":["CD8 • IFNG • IL2RA • CD4 • CD69 • NCAM1 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Proleukin (aldesleukin) • Ceplene (histamine)"],"overall_status":"Completed","enrollment":" Enrollment 84","initiation":"Initiation: 07/01/2009","start_date":" 07/01/2009","primary_txt":" Primary completion: 06/01/2014","primary_completion_date":" 06/01/2014","study_txt":" Completion: 06/01/2014","study_completion_date":" 06/01/2014","last_update_posted":"2017-11-29"}]